XFOR FY2029 EPS Lowered by Brookline Capital Management

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at Brookline Capital Management dropped their FY2029 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 5th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of $1.52 per share for the year, down from their previous estimate of $1.55. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.10. The company had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%.

XFOR has been the topic of several other research reports. Stifel Nicolaus set a $7.50 price target on X4 Pharmaceuticals in a report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of X4 Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research raised X4 Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 21st. Finally, HC Wainwright set a $3.50 price target on X4 Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.67.

X4 Pharmaceuticals Stock Up 5.7%

XFOR stock opened at $3.71 on Friday. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $26.83. The firm has a market cap of $42.33 million, a PE ratio of -0.37 and a beta of 0.51. The firm has a 50 day simple moving average of $3.40 and a 200 day simple moving average of $3.03. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 3.05.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Kingdon Capital Management L.L.C. grew its stake in X4 Pharmaceuticals by 41.8% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after acquiring an additional 2,063,000 shares in the last quarter. Pale Fire Capital SE grew its position in X4 Pharmaceuticals by 45.2% during the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after purchasing an additional 633,398 shares in the last quarter. Vanguard Group Inc. increased its stake in X4 Pharmaceuticals by 77.0% in the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock valued at $1,404,000 after buying an additional 178,593 shares during the period. Jane Street Group LLC increased its stake in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after buying an additional 51,544 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in X4 Pharmaceuticals by 9.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after buying an additional 43,320 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam R. Craig purchased 86,206 shares of the stock in a transaction dated Thursday, October 23rd. The shares were acquired at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the acquisition, the chairman owned 376,087 shares of the company’s stock, valued at $1,090,652.30. This represents a 29.74% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.37% of the stock is currently owned by company insiders.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.